v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues:    
Total revenues $ 19,355 $ 1,579
Operating expenses:    
Research and development 95,525 98,262
Selling, general and administrative 104,896 57,369
Cost of goods sold 160 0
Collaboration cost of sales 2,392 1,579
Total operating expenses 202,973 157,210
Operating loss (183,618) (155,631)
Interest and other expense, net (14,519) (8,868)
Non-cash interest expense on liabilities related to revenue participation right purchase agreements (18,816) (14,078)
Interest and other income, net 11,022 13,701
Change in fair value of derivative liabilities 1,500 (400)
Change in fair value of liabilities related to RPI Transactions (1,600) 3,900
Net loss $ (206,031) $ (161,376)
Net loss per share - basic $ (1.67) $ (1.36)
Net loss per share - diluted $ (1.67) $ (1.36)
Weighted-average number of shares used in computing net loss per share - basic 123,273 118,496
Weighted-average number of shares used in computing net loss per share - diluted 123,273 118,496
Other comprehensive (loss) gain:    
Unrealized loss on available-for-sale securities, net $ (1,838) $ (541)
Foreign currency translation adjustments (404) (312)
Comprehensive loss (208,273) (162,229)
Net Product Revenue [Member]    
Revenues:    
Total revenues 4,789 0
Collaboration Revenues [Member]    
Revenues:    
Total revenues 2,637 1,579
License and Milestone Revenues [Member]    
Revenues:    
Total revenues $ 11,929 $ 0